ODTX
Odyssey Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-28/100
Last price
18.28
▲ 0.15 (0.83%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
18.01
Prev close
18.13
Day high
18.84
Day low
17.83
Volume
161.90K
Market cap
$878.51M
P/E (TTM)
—
52W range
15.10 – 29.05
Day trading desk
Gap from prior close
-0.66%
Prior close 18.13
VWAP
18.32
-0.25% from price
Relative volume
0.58×
Quiet session
Session range
5.69%
17.83 – 18.84
Position in range
45%
Mid range
ATR (14D)
1.90
10.38% of price
Prior day high
20.84
PDH
Prior day low
18.06
PDL
Bid / ask spread
—
Quote not published
Session volume
157.69K
Avg 271.56K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-17.73%
-19.7%
1M
-32.22%
-33.7%
3M
+8.62%
+5.2%
6M
—
-15.0%
YTD
+11.33%
-2.7%
1Y
—
-15.8%
3Y
—
-81.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ODTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+12.79M
Net buying
Buy transactions
14
12.79M shares
Sell transactions
1
1.78K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
2.97M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 11, 26 | LEIDEN JEFFREY M Director |
— | 31.66K | — | Indirect |
| May 11, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 555.55K | $10.00M | Indirect |
| May 11, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 1.78K | $32.04K | Indirect |
| May 11, 26 | SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security |
— | 3.24M | — | Indirect |
| May 11, 26 | TPG GP A, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.39M | $25.00M | Indirect |
| May 11, 26 | TPG GP A, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
— | 1.88M | — | Indirect |
| May 11, 26 | CHU SHELLEY Director |
BUY | 11.11K | $200.00K | Direct |
| May 11, 26 | LI NAN LN Director |
BUY | 1.11M | $20.00M | Indirect |
| May 11, 26 | LI NAN LN Director |
— | 1.71M | — | Indirect |
| May 11, 26 | OPIPARI ANTHONY W M.D., PH.D. Officer |
— | 7.51K | — | Direct |
| May 11, 26 | GLICK GARY D. PH.D. Chief Executive Officer |
— | 27.39K | — | Direct |
| May 8, 26 | LEIDEN JEFFREY M Director |
BUY | 5.00K | $82.10K | Direct |
| May 8, 26 | HAAS JASON Chief Financial Officer |
BUY | 1.00K | $16.42K | Direct |
| May 8, 26 | DIMENSION CAPITAL II, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.11M | $20.00M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHU SHELLEY |
Director | 11.11K | Purchase |
DIMENSION CAPITAL II, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
GLICK GARY D. PH.D. |
Chief Executive Officer | 415.97K | Conversion of Exercise of derivative security |
HAAS JASON |
Chief Financial Officer | 62.91K | Purchase |
LEIDEN JEFFREY M |
Director | — | Conversion of Exercise of derivative security |
LI NAN LN |
Director | — | Purchase |
OPIPARI ANTHONY W M.D., PH.D. |
Officer | 7.50K | Conversion of Exercise of derivative security |
SR ONE CAPITAL MANAGEMENT, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
TPG GP A, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$878.51M
Enterprise value$583.01M
Revenue (TTM)$99.00K
Gross profit$-120.62M
EBITDA$-150.27M
Net income$-160.03M
EPS (TTM)$-7.55
Free cash flow—
Total cash$310.58M
Total debt$24.82M
Book value / share$8.80
Shares outstanding48.06M
Float20.05M
Short % of float5.24%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.19
PEG ratio—
Price / sales—
Price / book2.08
EV / revenue5,889.01
EV / EBITDA-3.88
Gross margin0.00%
Operating margin-156392.92%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity5.89
Current ratio11.36
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.98M | $4.47M | $1.04M | $0 | -33.5% |
| Operating revenue | $2.98M | $4.47M | $1.04M | $0 | -33.5% |
| Research & development | $126.62M | $112.58M | $112.28M | $101.75M | +12.5% |
| Selling, general & admin | $37.52M | $27.12M | $22.20M | $21.02M | +38.4% |
| Total operating expense | $164.13M | $139.69M | $134.48M | $122.78M | +17.5% |
| Operating income | -$161.16M | -$135.22M | -$133.44M | -$122.78M | -19.2% |
| Net interest income | $6.33M | $8.47M | $8.46M | $3.63M | -25.3% |
| Pre-tax income | -$149.57M | -$128.85M | -$125.49M | -$124.32M | -16.1% |
| Tax provision | -$927.00K | $469.00K | $447.00K | $347.00K | -297.7% |
| Net income | -$148.65M | -$129.32M | -$125.94M | -$124.67M | -14.9% |
| Net income to common | -$148.65M | -$130.40M | -$130.92M | -$124.67M | -14.0% |
| Basic EPS | -5.39 | -4.73 | -1.32 | -4.52 | -13.9% |
| Diluted EPS | -5.39 | -4.73 | -1.32 | -4.52 | -13.9% |
| EBIT | -$149.56M | -$128.83M | -$125.16M | -$124.03M | -16.1% |
| EBITDA | -$144.65M | -$123.64M | -$120.25M | -$121.26M | -17.0% |
| Basic shares | 27.56M | 27.56M | 99.23M | 27.56M | 0.0% |
| Diluted shares | 27.56M | 27.56M | 99.23M | 27.56M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $41.69M | $59.14M | $52.55M | $241.04M | -29.5% |
| Cash & short-term investments | $181.36M | $129.35M | $187.00M | $241.04M | +40.2% |
| Total current assets | $190.66M | $135.51M | $192.54M | $248.71M | +40.7% |
| Property, plant & equipment | $26.01M | $39.47M | $46.73M | $52.77M | -34.1% |
| Goodwill & intangibles | $14.59M | $13.92M | $14.46M | $14.06M | +4.8% |
| Total assets | $269.79M | $197.44M | $286.52M | $317.15M | +36.6% |
| Total current liabilities | $26.48M | $28.41M | $22.09M | $22.80M | -6.8% |
| Long-term debt | — | — | — | $4.76M | — |
| Total debt | $27.11M | $31.01M | $34.38M | $42.49M | -12.6% |
| Total liabilities | $758.07M | $579.96M | $549.23M | $461.77M | +30.7% |
| Retained earnings | -$568.14M | -$419.49M | -$289.09M | -$158.17M | -35.4% |
| Shareholder equity | -$488.28M | -$382.53M | -$262.71M | -$144.62M | -27.6% |
| Working capital | $164.18M | $107.09M | $170.45M | $225.91M | +53.3% |
| Net tangible assets | -$502.87M | -$396.44M | -$277.17M | -$158.68M | -26.8% |
| Shares issued | 47.17M | 47.17M | 47.17M | 47.17M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$148.65M | -$129.32M | -$125.94M | -$124.67M | -14.9% |
| Depreciation & amortisation | $4.91M | $5.19M | $4.91M | $2.76M | -5.4% |
| Stock-based compensation | $14.32M | $8.69M | $6.26M | $5.52M | +64.9% |
| Change in working capital | -$4.73M | -$3.31M | $896.00K | -$544.00K | -43.0% |
| Operating cash flow | -$129.47M | -$117.47M | -$112.73M | -$99.84M | -10.2% |
| Capital expenditure | -$1.23M | -$764.00K | -$5.06M | -$13.03M | -61.3% |
| Investing cash flow | -$103.94M | $96.78M | -$165.02M | -$13.03M | -207.4% |
| Financing cash flow | $215.65M | $26.98M | $92.08M | $182.72M | +699.3% |
| Free cash flow | -$130.70M | -$118.23M | -$117.78M | -$112.87M | -10.5% |
| End cash position | $44.90M | $62.35M | $56.00M | $241.67M | -28.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $959.00K | $1.92M | — |
| Operating revenue | $0 | $0 | $959.00K | $1.92M | — |
| Research & development | $36.23M | $32.32M | $30.23M | $38.77M | +12.1% |
| Selling, general & admin | $10.51M | $7.35M | $13.22M | $7.95M | +43.0% |
| Total operating expense | $46.74M | $39.67M | $43.45M | $46.73M | +17.8% |
| Operating income | -$46.74M | -$39.67M | -$42.49M | -$44.81M | -17.8% |
| Net interest income | $2.81M | $1.70M | $870.00K | $1.15M | +65.6% |
| Pre-tax income | -$52.80M | -$38.20M | -$41.20M | -$38.30M | -38.2% |
| Tax provision | -$8.00K | $63.00K | $30.00K | $140.00K | -112.7% |
| Net income | -$52.79M | -$38.26M | -$41.23M | -$38.44M | -38.0% |
| Net income to common | -$52.79M | -$38.26M | -$41.23M | -$38.44M | -38.0% |
| Basic EPS | -1.74 | -0.81 | -1.50 | -1.39 | -114.5% |
| Diluted EPS | -1.74 | -0.81 | -1.50 | -1.39 | -114.5% |
| EBIT | -$52.78M | -$38.19M | -$41.20M | -$38.29M | -38.2% |
| EBITDA | -$51.73M | -$37.02M | -$39.94M | -$36.99M | -39.8% |
| Basic shares | 30.28M | 47.17M | 27.56M | 27.56M | -35.8% |
| Diluted shares | 30.28M | 47.17M | 27.56M | 27.56M | -35.8% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $82.03M | $35.72M | +129.7% |
| Cash & short-term investments | $310.57M | $175.75M | +76.7% |
| Total current assets | $321.46M | $185.10M | +73.7% |
| Property, plant & equipment | $21.92M | $24.48M | -10.5% |
| Goodwill & intangibles | $14.19M | $14.23M | -0.3% |
| Total assets | $483.85M | $229.07M | +111.2% |
| Total current liabilities | $28.30M | $22.21M | +27.4% |
| Total debt | $24.82M | $26.13M | -5.0% |
| Total liabilities | $62.63M | $752.76M | -91.7% |
| Retained earnings | -$659.19M | -$606.40M | -8.7% |
| Shareholder equity | $421.22M | -$523.69M | +180.4% |
| Working capital | $293.17M | $162.89M | +80.0% |
| Net tangible assets | $407.04M | -$537.93M | +175.7% |
| Shares issued | 48.03M | 47.17M | +1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$52.79M | -$38.26M | -$41.23M | -$38.44M | -38.0% |
| Depreciation & amortisation | $1.04M | $1.17M | $1.27M | $1.30M | -10.9% |
| Stock-based compensation | $5.67M | $2.59M | $3.70M | $2.99M | +119.2% |
| Change in working capital | $1.17M | -$7.19M | $2.42M | -$5.28M | +116.3% |
| Operating cash flow | -$34.51M | -$41.03M | -$34.26M | -$38.62M | +15.9% |
| Capital expenditure | -$186.00K | -$148.00K | -$29.00K | -$927.00K | -25.7% |
| Investing cash flow | -$211.44M | $34.80M | $23.30M | $34.13M | -707.6% |
| Financing cash flow | $292.16M | $484.00K | $118.72M | $200.00K | +60,263.6% |
| Free cash flow | -$34.69M | -$41.18M | -$34.29M | -$39.55M | +15.8% |
| End cash position | $85.48M | $39.17M | $166.21M | $58.12M | +118.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.85 | -1.27 | -49.1% |
| Mar 2026 | -1.28 | -6.75 | -427.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.93 | 3 | $0 | — |
| Next quarter | -1.01 | 3 | $0 | — |
| Current year | -4.26 | 3 | $0 | — |
| Next year | -4.36 | 3 | $0 | 0.0% |
Analyst targets & ownership
Mean target$35.75
High target$44.00
Low target$29.00
Implied upside95.57%
Analyst count4
ConsensusNONE
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders6.19%
Held by institutions83.12%
Institutions holding66
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
20.50
-10.82% from price
SMA 20
21.87
-16.41% from price
SMA 50
22.56
-18.95% from price
SMA 100
20.02
-8.69% from price
SMA 200
—
—
EMA 12
20.70
-11.71% from price
EMA 26
21.78
-16.07% from price
EMA 50
21.73
-15.88% from price
RSI (14)
36.4
Neutral
MACD (12,26,9)
-1.07
Hist -0.46
ATR (14)
1.90
10.38% of price
Realised vol 30D
90.0%
Annualised
Bollinger upper
25.57
20, 2σ
Bollinger lower
18.17
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.26
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
90.0%
Annualised
Market vol 1Y
12.2%
SPY, annualised
Max drawdown 1Y
-37.0%
Peak to trough
Max drawdown 5Y
-37.0%
Peak to trough
ATR 14
1.90
10.38% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.21M
Prior 2.25M
Change vs prior
-1.8%
Shorts covering
% of float
5.24%
Normal
% of shares out
4.60%
Against total outstanding
Days to cover
11.6
Crowded exit
Float
20.05M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Aug 7, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jun 18, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jun 2, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jun 2, 26 | TD Cowen | INITIATED | — | Buy |
| Jun 2, 26 | Wedbush | INITIATED | — | Outperform |
| Jun 2, 26 | JP Morgan | INITIATED | — | Overweight |
| Jun 2, 26 | Oppenheimer | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-09
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-23
Periodic Financial Reports
10-Q · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-11
Offering Registrations
S-1MEF · 2026-05-07
Trading Registrations
8-A12B · 2026-05-05
Headlines
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
GlobeNewswire · 1d ago
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
GlobeNewswire · 21d ago
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
Insider Monkey · 24d ago
HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target
MT Newswires · 41d ago
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire · 42d ago
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
Simply Wall St. · 58d ago
Evotec and Odyssey collaborate on AI-enabled R&D
Pharmaceutical Technology · 61d ago
Odyssey Therapeutics: Q2 Earnings Snapshot
Associated Press · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.